Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02231749 · ClinicalTrials.gov registry record · Phase 3
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,096
- Enrollment target
NCT02231749 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,096 participants.
The verdict
NCT02231749, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,096 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.
Interventions
- DRUG Sunitinib
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,096 participants |
| Start Date | 2014-10-16 |
| Est. Completion | 2025-03-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02231749
The ClinicalTrials.gov registry entry for NCT02231749 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,096 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sunitinib is the first listed.
NCT02231749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02231749 about?
NCT02231749 is a clinical study titled "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)". The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.
What is the current status of trial NCT02231749?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,096 participants. The study started on 2014-10-16. Estimated completion is 2025-03-21.
What interventions are being tested in trial NCT02231749?
The interventions under investigation include: Sunitinib (DRUG), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02231749?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.